Clinical trial · Observational
In Vitro NSCLC EGFR-Mutant Models for Drug Sensitivity Testing
Targeting EGFR in Lung Cancer: Role of EGFR Mutation State and Bypass Routes in Drug Response and Resistance
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
The PRECISE-EGFR study is a prospective, observational project designed to generate patient-derived in vitro models (cell cultures and organoids) from individuals with non-small cell lung cancer (NSCLC) carrying EGFR mutations. These models will be used to evaluate sensitivity to different anti-EGFR therapies and explore mechanisms of drug resistance. Using residual biological samples collected during routine clinical practice, the study will not interfere with patient care. Researchers will also compare the molecular characteristics of the models with the original tumors to ensure reliability. The overall aim is to improve precision oncology approaches, identifying the most effective treatments for specific EGFR mutation subtypes while minimizing toxicity and resistance.
Conditions
Conditions (2)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Carcinoma, Non-Small-Cell Lung | Lung Non-Small Cell Carcinoma | ALIAS | 0.90 |
| EGFR Gene Mutation | — | UNRESOLVED | — |
Interventions
Interventions (0)
Data not yet available
Design
Arms and outcomes
Arms (0)
[]Primary outcomes (1)
- measure
- Generate in vitro cellular models derived from tumors of patients with NSCLC carrying EGFR mutations, using residual biological samples, to be used for evaluating sensitivity to anti-EGFR drugs.
- timeFrame
- Throughout the study, 3 years
- description
- The primary objective is to generate in vitro cellular models derived from tumors of patients with non-small cell lung cancer (NSCLC) harboring EGFR mutations, using residual biological samples, to be used for evaluating sensitivity to anti-EGFR drugs.
Secondary outcomes (2)
- measure
- Degree of molecular concordance between the original tumor and derived models
- timeFrame
- Throughout the study, 3 years
- description
- Compare the molecular characteristics of the obtained models with those of the original tumor in order to verify their biological concordance.
- measure
- Variation in cell viability in in vitro models following treatment with anti-EGFR drugs
- timeFrame
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 18 Years
Show eligibility criteria text
Inclusion Criteria: * Age ≥ 18 years. * Diagnosis of non-small cell lung cancer (NSCLC), regardless of the line of treatment. * Documented presence of an EGFR mutation. * Availability of residual biological material obtained from diagnostic or therapeutic procedures performed as part of routine clinical practice. * Signed written informed consent for study participation. Exclusion Criteria: * Patients who have not provided written informed consent will be excluded from the study.
References
Publications (0)
Data not yet available